COMP <GO>
RANI vs CRBP // RSI-14 & 200D SMA MOMENTUM
Rani Therapeutics Holdings Inc. (Class A) (NASDAQ) VS. Corbus Pharmaceuticals Holdings Inc. (NASDAQ) • 15-METRIC TALLY: RANI 3
— CRBP 0
▲ RSI-14 & 200D SMA MOMENTUM LEADER: RANI
LAST: $0.56 (+0.73%) • MKT CAP: $76.9M
rsi-technicals
27.2
LAST: $3.87 (-1.15%) • MKT CAP: $75.7M
rsi-technicals
22.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RANI VS. CRBP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RANI | CRBP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -22.28% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 58.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 2/9 | +3.00 | RANI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 27.2 | 22.3 | +4.90 | RANI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $76.9M | $75.7M | $1.2M | RANI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RANI REV | CRBP REV | RANI GROSS % | CRBP GROSS % | RANI FCF | CRBP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.6M | $238.9M | — | — | -$18.8M | -$64.5M |
| FY 2024 | $1.0M | $136.4M | — | — | -$35.8M | -$41.8M |
| FY 2023 | $185.1M | $126.2M | — | — | -$51.2M | -$36.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RANI // BETA —
CRBP // BETA —